Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard sold 7,584 shares of the firm’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the sale, the vice president now directly owns 7,584 shares in the company, valued at approximately $151,680. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Heron Therapeutics Inc (HRTX) traded down $0.25 during mid-day trading on Friday, reaching $21.40. The company’s stock had a trading volume of 1,141,376 shares, compared to its average volume of 1,079,933. The company has a market cap of $1,170.00, a PE ratio of -5.65 and a beta of 2.12. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12. Heron Therapeutics Inc has a 52-week low of $12.25 and a 52-week high of $22.00.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. equities analysts expect that Heron Therapeutics Inc will post -3.39 earnings per share for the current year.
HRTX has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Monday, September 25th. Mizuho initiated coverage on Heron Therapeutics in a research note on Tuesday, September 26th. They set a “buy” rating and a $28.00 price objective on the stock. Northland Securities initiated coverage on Heron Therapeutics in a research note on Wednesday, September 27th. They set an “outperform” rating and a $40.00 price objective on the stock. Noble Financial reaffirmed a “buy” rating and set a $24.00 price objective on shares of Heron Therapeutics in a research note on Friday, October 6th. Finally, Oppenheimer assumed coverage on Heron Therapeutics in a research note on Monday, October 30th. They set a “buy” rating and a $27.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $28.82.
Hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its holdings in Heron Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 2,383 shares in the last quarter. Quantbot Technologies LP grew its holdings in shares of Heron Therapeutics by 2,619.6% in the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Heron Therapeutics in the 3rd quarter valued at about $206,000. Jane Street Group LLC bought a new position in shares of Heron Therapeutics in the 3rd quarter valued at about $223,000. Finally, HighTower Advisors LLC grew its holdings in shares of Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares in the last quarter. Hedge funds and other institutional investors own 98.78% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/01/12/kimberly-manhard-sells-7584-shares-of-heron-therapeutics-inc-hrtx-stock.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.